Atea Pharmaceuticals (AVIR) Common Equity (2019 - 2026)

Atea Pharmaceuticals' Common Equity history runs 8 years deep, the most recent figure standing at $233.7 million for Q1 2026.

• In Q1 2026, Common Equity fell 43.15% year-over-year to $233.7 million; the TTM figure through Mar 2026 stood at $233.7 million (down 43.15% YoY), while the FY2025 annual figure was $275.4 million, down 37.24% from the prior year.
• Common Equity was $233.7 million for Q1 2026 at Atea Pharmaceuticals, down from $275.4 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $679.9 million in Q1 2022 to a low of $233.7 million in Q1 2026.
• Historically, Common Equity has averaged $498.8 million across 5 years, with a median of $504.4 million in 2024.
• The sharpest annual moves came in 2022 and 2026: Common Equity gained 15.97% in 2022, then sank 43.15% in 2026.
• A 5-year view of Common Equity shows it stood at $640.6 million in 2022, then slipped by 13.33% to $555.2 million in 2023, then fell by 20.95% to $438.9 million in 2024, then slumped by 37.24% to $275.4 million in 2025, then decreased by 15.15% to $233.7 million in 2026.
• The last three Common Equity figures came in at $233.7 million (Q1 2026), $275.4 million (Q4 2025), and $315.8 million (Q3 2025), per Business Quant data.